Publication:
Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group

2
0

Issued Date

2020

Resource Type

Article

File Type

application/pdf

ISSN

10428194

DOI

10.1080/10428194.2020.1780586

Other identifier(s)

2-s2.0-85087357897

Rights Holder(s)

Scopus

Bibliographic Citation

Leukemia and Lymphoma. Vol 61, No.11 (2020), p.2614-2621

Suggested Citation

Wudhikarn K., Bunworasate U., Julamanee J., Lekhakula A., Ekwattanakit S., Khuhapinant A., Niparuck P., Chuncharunee S., Numbenjapon T., Prayongratana K., Kanitsap N., Wongkhantee S., Makruasi N., Wong P., Norasetthada L., Nawarawong W., Sirijerachai C., Chansung K., Suwanban T., Praditsuktavorn P., Intragumtornchai T., On Behalf Of Thai Lymphoma Study Group Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group. Leukemia and Lymphoma. Vol 61, No.11 (2020), p.2614-2621. doi:10.1080/10428194.2020.1780586 Retrieved from: https://hdl.handle.net/20.500.14740/4402

Title

Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group

Author(s)

Wudhikarn K.
 Bunworasate U.
 Julamanee J.
 Lekhakula A.
 Ekwattanakit S.
 Khuhapinant A.
 Niparuck P.
 Chuncharunee S.
 Numbenjapon T.
 Prayongratana K.
 Kanitsap N.
 Wongkhantee S.
 Makruasi N.
 Wong P.
 Norasetthada L.
 Nawarawong W.
 Sirijerachai C.
 Chansung K.
 Suwanban T.
 Praditsuktavorn P.
 Intragumtornchai T.
 On Behalf Of Thai Lymphoma Study Group

Abstract

Event-free survival at 12 months (EFS12) is a surrogate endpoint for long-term outcomes in many histologic lymphoma subtypes. However, most reports have primarily investigated the implication of EFS12 in advanced-stage non-Hodgkin lymphoma (NHL). There are limited data regarding the significance of EFS12 in early-stage NHL. Herein, we evaluated the prognostic significance of EFS12 in patients with stage 1 diffuse large B-cell lymphoma (DLBCL). Out of 282 patients with stage 1 DLBCL who received intensive therapy, 227 (80.5%) achieved EFS12. The 4-year overall survival (OS) was 91.4% and 4.0% for patients who achieved and failed to achieve EFS12, respectively. Multivariable analyses demonstrated response to treatment and achievement of EFS12 as independent predictors for OS. In conclusion, our study demonstrated EFS12 as a powerful prognostic factor for stage 1 DLBCL. Further validation in more extensive prospective studies is warranted. © 2020 Informa UK Limited, trading as Taylor & Francis Group.

Subject(s)

Adult
 Advanced cancer
 Aged
 Article
 Cancer patient
 Cancer prognosis
 Cancer radiotherapy
 Cancer staging
 Cancer survival
 Controlled study
 Diffuse large B cell lymphoma
 Event free survival
 Female
 Histology
 Human
 Human tissue
 Intensive care
 Major clinical study
 Male
 Multivariate analysis
 Outcome assessment
 Overall survival
 Predictive value
 Priority journal
 Prospective study
 Systemic therapy
 Thailand
 Treatment response

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/4402

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By